SCHEMBL1785152

SCHEMBL1785152

O=C(Cl)C[C@H]1C[C@@H]2CC[C@H]1C2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
RAB9A P51151 2/20 0.54
NPC1 O15118 1/20 0.54
P2RX7 Q99572 1/20 0.47
HPGD P15428 2/20 0.43
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 1/20 0.41
LMNA P02545 3/20 0.40
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 2/20 0.39
TP53 P04637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SIRT5 Q9NXA8 1/20 0.39
EPHX2 P34913 2/20 0.38
RXFP1 Q9HBX9 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1785153 1.00 MEN1 (0.54) MEN1KMT2ARAB9ANPC1P2RX7
SCHEMBL10489459 0.84 MEN1 (0.56) MEN1KMT2ARAB9ANPC1P2RX7
SCHEMBL11603597 0.84 MEN1 (0.56) MEN1KMT2ARAB9ANPC1P2RX7
SCHEMBL5449679 0.83 MEN1 (0.54) MEN1KMT2ARAB9ANPC1P2RX7
SCHEMBL1527314 0.83 MEN1 (0.54) MEN1KMT2ARAB9ANPC1P2RX7
SCHEMBL189532 0.83 MEN1 (0.54) MEN1KMT2ARAB9ANPC1P2RX7
SCHEMBL7269130 0.83 MEN1 (0.54) MEN1KMT2ARAB9ANPC1P2RX7
SCHEMBL20573120 0.83 MEN1 (0.54) MEN1KMT2ARAB9ANPC1P2RX7
SCHEMBL20573107 0.83 MEN1 (0.54) MEN1KMT2ARAB9ANPC1P2RX7
SCHEMBL1527315 0.83 MEN1 (0.54) MEN1KMT2ARAB9ANPC1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859549-B2 Potassium channel modulators ABBVIE, INC. (US) 2014-10-14 US disclosed
US-8629143-B2 Potassium channel modulators ABBVIE INC. (US) 2014-01-14 US disclosed
US-20120289500-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-11-15 US disclosed
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289500-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNJ2 MEN1 1274/4885KMT2A 574/4885RAB9A 1391/4885
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNQ3 MEN1 1418/4885KMT2A 474/4885RAB9A 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.